The impact of comparative effectiveness research on health and health care spending

Journal of Health Economics

Volumn 30, Issue 4, 2011, Pages 695-706

  Basu, Anirban ^a   Jena, Anupam B ^b   Philipson, Tomas J ^c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b HARVARD UNIVERSITY   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

Comparative effectiveness analysis; Cost effectiveness analysis; Technology assessment

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE;

COMPARATIVE STUDY; COST-BENEFIT ANALYSIS; HEALTH CARE; HEALTH POLICY; HEALTH SERVICES; MENTAL HEALTH; PUBLIC SPENDING; RESEARCH WORK;

ARTICLE; COMPARATIVE EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG WITHDRAWAL; HEALTH CARE COST; HEALTH CARE FINANCING; HEALTH CARE MANAGEMENT; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH INSURANCE; HEART FAILURE; HUMAN; MEDICAL RESEARCH; MOTOR DYSFUNCTION; SCHIZOPHRENIA; SIDE EFFECT; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS AS TOPIC; COMPARATIVE EFFECTIVENESS RESEARCH; HEALTH EXPENDITURES; HEALTH POLICY; HUMANS; MEDICAID; PATIENT PARTICIPATION; PHYSICIAN'S PRACTICE PATTERNS; SCHIZOPHRENIA; TREATMENT OUTCOME; UNITED STATES;

EID: 79960928908     PISSN: 01676296     EISSN: 18791646     Source Type: Journal    
DOI: 10.1016/j.jhealeco.2011.05.012     Document Type: Article

References (38)

1. Ascher-Svanum H., Zhu B., Faries D.E., et al. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry 2010, 10(2):1-7.
2. Banthin J.S., Miller G.E. Trends in prescription drug expenditures by medicaid enrollees. Medical Care 2006, 44. I-27-I-35.
3. Basu A. Individualization at the heart of comparative effectiveness research: the time for i-CER has come. Medical Decision Making 2009, 29(6):N9-N11.
4. Basu A. Economics of individualization in comparative effectiveness research and a basis for a patient-centered healthcare. Journal of Health Economics 2011, 30(3):549-559.
5. Bruen, B., Ghosh, A., 2004. Medicaid prescription drug spending and use. Kaiser commission on Medicaid and the uninsured issue paper. (accessed 21.12.09). http://www.kff.org/medicaid/upload/Medicaid-Prescription-Drug-Spending-and-Use.pdf.
6. Chernew M.E., Rosen A., Fendrick A.M. Value-based insurance design. Health Affairs 2007, 26(2):w195-w203.
7. Clancy C., Collins F.S. Patient-centered outcomes research Institute: The Intersection of Science and Health Care. Science Translational Medicine 2010, 2(7):1-3.
8. Federal Coordinating Council for Comparative Effectiveness Research. 2009. Report to the President and the Congress. June 30.
9. Fendrick A.M., Smith D.G., Chernew M.E., Shah S.N. A benefit-based copay for prescription drugs: patient contribution based on total benefits, not drug acquisition cost. The American Journal of Managed Care 2001, 7:861-867.
10. Gilmer T.P., Dolder C.R., Lacro J.P., Folsom D.P., Lindamer L., Garcia P., Jeste D.V. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. The American Journal of Psychiatry 2004, 161(4):692-699.
11. Goldman D., Philipson T.J. Integrated insurance design in the presence of multiple medical technologies. American Economic Review 2007, 97(2):427-432.
12. IOM Initial National Priorities for Comparative Effectiveness Research: Committee on Comparative Effectiveness Research Prioritization Board on Health Care Services, June 2009.
13. Jena A., Philipson T. Cost-effectiveness analysis and innovation. Journal of Health Economics 2008, 27(5):1224-1236.
14. A. Jena, T. Philipson, 2009. Endogenous cost-effectiveness analysis in health care technology adoption, NBER Working Paper 15032, Cambridge, MA.
15. Jena A., Mechoulan S., Philipson T. Altruism and innovation in health care. Journal of Law and Economics 2010, 53(3):497-518.
16. Kane J.M. Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence. Journal Clinical Psychiatry 2004, 65(Suppl. 9):16-20.
17. Leucht S., Corves C., Arbter D., Engel R.R., Li C., Davis J.M. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009, 373:31-41.
18. Lewin Group, 2000. Access and utilization of new antidepressant and antipsychotic medications. Report submitted to The Office of the Assistant Secretary for Planning and Evaluation and The National Institute of Mental Health, U.S. Department of Health and Human Services. http://aspe.hhs.gov/health/reports/Psychmedaccess/.
19. Lenert L., Sturley A.P., Rapaport M.H., Chavez S., Mohr P., Rupnow M. Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative syndrome scale scores. Schizophrenia Research 2004, 71:155-165.
20. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., Hsiao J.K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 2005, 353:1209-1223.
21. Malani, A., Philipson, T., 2011. Government regulation of medical product safety and innovation, Handbook of Pharmaceuticals Markets, edited by P Danzon and S. Nicholson, Oxford University Press, forthcoming.
22. Matchar D.B., McCrory D.C., Orlando L.A., Patel M.R., Patel U.D., Patwardhan M.B., Powers B., Samsa G.P., Gray R.N. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin ii receptor blockers for treating essential hypertension. Annals of Internal Medicine 2008, 148(1):16-29.
23. Meltzer H.Y. The metabolic consequences of long-term treatment with olanzapine, quetiapine and risperidone: are there differences?. International Journal of Neuropsychopharmacology 2005, 8:153-156.
24. Meltzer H.Y. Atypical antipsychotic drugs have their merits. Lancet 2009, 373:1007.
25. NIMH Perspective on Antipsychotic Reimbursement: Using Results from CATIE. (accessed 17.09.09). http://www.nimh.nih.gov/about/director/updates/2006/nimh-perspective-on-antipsychotic-reimbursement-using-results-from-the-catie-cost-effectiveness-study.shtml.
26. New York Times Editorial, 2005. Comparing schizophrenia drugs. September 21.
27. Nissen S.E., Wolsky K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. New England Journal of Medicine 2007, 356(24):2457-2471.
28. Pauly M.V., Blavin F.E. Moral hazard in insurance, value-based cost sharing, and the benefits of blissful ignorance. Journal of Health Economics 2008, 27:1407-1417.
29. Polinski J.M., Wang P.S., Fisher M.A. Medicaid's prior authorization program and access to atypical antipsychotic medications. Health Affairs 2007, 26(3):750-760.
30. Polsky D., Doshi J.A., Bauer M.S., Glick H.A. Clinical trial-based cost-effectiveness analyses of antipsychotic use. The American Journal of Psychiatry 2006, 163:2047-2056.
31. Rosenheck, R.A., et al., 2007. CATIE Investigator's Educations Series.
32. Rosenheck R.A., et al. Cost-effectiveness of second generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. American Journal of Psychiatry 2006, 163(12):2080-2089.
33. Schnider L.S., Tariot P.N., Dagerman K.S., Davis S.M., Hsiao J.K., Ismail M.S., Lebowitz B.D., Lyketsos C.G., Ryan J.M., Stroup T.S., Sultzer D.L., Weintraub D., Lieberman J.A. for the CATIE-AD Study Group. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. New England Journal of Medicine 2006, 355(15):1525-1538.
34. Stinnett A., Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Medical Decision Making 1998, 18:S68-S80.
35. Soumerai S.B., Law M.R. Cost-effectiveness of schizophrenia pharmacotherapy. American Journal Psychiatry 2007, 164:678.
36. Wilt T.J., MacDonald R., Rutks I., Shamliyan T.A., Taylor B.C., Kane R.L. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Annals of Internal Medicine 2008, 148(6):435-448.
37. Weiden P.J., Oltson M. Cost of relapse in schizophrenia. Schizophrenia Bulletin 1995, 21(3):419-429.
38. Wu E.Q., Shi L., Birnbaum H., Hudson T., Kessler R. Annual prevalence of diagnosed schizophrenia in the USA: a claims data analysis approach. Psychological Medicine 2006, 36:1535-1540.